Current perspectives on statins
Current perspectives on statins
复制标题
DOI：
10.1161/01.cir.101.2.207
复制
发表时间：
2000-01-18
期刊：
影响因子：
37.8
通讯作者：
Linton, MF
中科院分区：
文献类型：
--
作者：
Maron, DJ;Fazio, S;Linton, MF
他汀类药物（HMG-CoA还原酶抑制剂）被广泛用于治疗高胆固醇血症。它们竞争性地抑制HMG-CoA还原酶，比其他降胆固醇药物更能降低LDL水平，并降低高甘油三酯血症患者的甘油三酯水平。他汀类药物耐受性良好，具有良好的安全记录。在有或无冠心病、有或无高胆固醇的患者中进行的临床试验一致表明，他汀类药物可使主要冠状动脉事件的相对风险降低约30%，并在基线风险较高的患者中产生更大的绝对获益。提出的机制包括对血浆脂蛋白、内皮功能、斑块结构和稳定性、血栓形成和炎症的有利作用。独立于LDL降低的机制可能在这些药物的临床获益中发挥重要作用，并可能最终将其适应症从降脂药扩展到抗动脉粥样硬化药。
Statins (HMG-CoA reductase inhibitors) are used widely for the treatment of hypercholesterolemia. They inhibit HMG-CoA reductase competitively, reduce LDL levels more than other cholesterol-lowering drugs, and lower triglyceride levels in hypertriglyceridemic patients. Statins are well tolerated and have an excellent safety record. Clinical trials in patients with and without coronary heart disease and with and without high cholesterol have demonstrated consistently that statins reduce the-relative risk of major coronary events by approximate to 30% and produce a greater absolute benefit in patients with higher baseline risk. Proposed mechanisms include favorable effects on plasma lipoproteins, endothelial function, plaque architecture and stability, thrombosis, and inflammation. Mechanisms independent of LDL lowering may play an important role in the clinical benefits conferred by these drugs and may ultimately broaden their indication from lipid-lowering to antiatherogenic agents.